Gene Doping

Abstract

Together with the rapidly increasing knowledge on genetic therapies as a promising new branch of regular medicine, the issue has arisen whether these techniques might be abused in the field of sports. Previous experiences have shown that drugs that are still in the experimental phases of research may find their way into the athletic world. Both the World Anti-Doping Agency (WADA) and the International Olympic Committee (IOC) have expressed concerns about this possibility. As a result, the method of gene doping has been included in the list of prohibited classes of substances and prohibited methods. This review addresses the possible ways in which knowledge gained in the field of genetic therapies may be misused in elite sports. Many genes are readily available which may potentially have an effect on athletic performance. The sporting world will eventually be faced with the phenomena of gene doping to improve athletic performance. A combination of developing detection methods based on gene arrays or proteomics and a clear education program on the associated risks seems to be the most promising preventive method to counteract the possible application of gene doping.

Key words

Doping - gene therapy - Epo - IGF

References

• 1 Abraham M D, Kaal H L, Cohen P DA. Licit and illicit drug use in the Netherlands 2001. Amsterdam; CEDRO/Mets en Schil 2002
• 2 Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo M G, Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.  Sci. 2002;  296 2410-2413
• 3 Andersen J L, Schjerling P, Saltin B. Muscle, genes and athletic performance.  Sci Am. 2000;  283 48-55
• 4 Arruda V R, Fields P A, Milner R, Wainwright L, De Miguel M P, Donovan P J, Herzog R W, Nichols T C, Biegel J A, Razavi M, Dake M, Huff D, Flake A W, Couto L, Kay M A, High K A. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV‐2 vector in males.  Mol Ther. 2001;  4 586-592
• 5 Barese C N, Goebel W S, Dinauer M C. Gene therapy for chronic granulomatous disease.  Expert Opin Biol Ther. 2004;  4 1423-1434
• 6 Barton-Davis E R, Shoturma D I, Musaro A, Rosenthal N, Sweeney H L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function.  Proc Natl Acad Sci USA. 1998;  95 15603-15607
• 7 Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner J M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.  Circul. 1998;  97 1114-1123
• 8 Bogdanovich S, Krag T O, Barton E R, Morris L D, Whittemore L A, Ahima R S, Khurana T S. Functional improvement of dystrophic muscle by myostatin blockade.  Nature. 2002;  420 418-421
• 9 Cavazzana-Calvo M, Fischer A. Efficacy of gene therapy for SCID is being confirmed.  Lancet. 2004;  364 2155-2156
• 10 Chenuaud P, Larcher T, Rabinowitz J E, Provost N, Cherel Y, Casadevall N, Samulski R J, Moullier P. Autoimmune anemia in macaques following erythropoietin gene therapy.  Blood. 2004;  103 3303-3304
• 11 Cohen-Haguenauer O, Rosenthal F, Gansbacher B, Bolhuis R, Dorsch-Hasler K, Eshhar Z, Gahrton G, Hokland P, Melani C, Rankin E, Thielemans K, Vile R, Zwierzina H, Cichutek K. Opinion paper on the current status of the regulation of gene therapy in Europe.  Hum Gene Ther. 2002;  13 2085-2110
• 12 Cummiskey J. Report on the IOC MC gene therapy medicine and sport 1-1-2002. Lausanne; IOC 2002
• 13 DeFrancesco L. The faking of champions.  Nat Biotechnol. 2004;  22 1069-1071
• 14 DoCoNed .Annual report 2001. Dopingcontrole Nederland' Capelle aan den IJssel. DoCoNed 2002
• 15 Gao G, Lebherz C, Weiner D J, Grant R, Calcedo R, McCullough B, Bagg A, Zhang Y, Wilson J M. Erythropoietin gene therapy leads to autoimmune anemia in macaques.  Blood. 2004;  103 3300-3302
• 16 Griscelli F, Opolon P, Saulnier P, Mami-Chouaib F, Gautier E, Echchakir H, Angevin E, Le C T, Bataille V, Squiban P, Tursz T, Escudier B. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.  Gene Ther. 2003;  10 386-395
• 17 Hacein-Bey-Abina S, Le D F, Carlier F, Bouneaud C, Hue C, De Villartay J P, Thrasher A J, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies E G, Kuis W, Leiva L, Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.  N Engl J Med. 2002;  346 1185-1193
• 18 Huard J, Li Y, Peng H, Fu F H. Gene therapy and tissue engineering for sports medicine.  J Gene Med. 2003;  5 93-108
• 19 Kay M A, Manno C S, Ragni M V, Larson P J, Couto L B, McClelland A, Glader B, Chew A J, Tai S J, Herzog R W, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake A W, High K A. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.  Nat Genet. 2000;  24 257-261
• 20 Kimmelman J. Recent developments in gene transfer: risk and ethics.  BMJ. 2005;  330 79-82
• 21 Labrie F, Luu-The V, Calvo E, Martel C, Cloutier J, Gauthier S, Belleau P, Morissette J, Levesque M H, Labrie C. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid.  J Endocrinol. 2005;  184 427-433
• 22 Lage J M, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis.  Neurol. 2002;  58 665
• 23 Lasne F, Martin L, de Ceaurriz J, Larcher T, Moullier P, Chenuaud P. “Genetic Doping” with erythropoietin cDNA in primate muscle is detectable.  Mol Ther. 2004;  10 409-410
• 24 Lee S, Barton E R, Sweeney H L, Farrar R P. Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats.  J Appl Physiol. 2004;  96 1097-1104
• 25 Lee S J, McPherron A C. Regulation of myostatin activity and muscle growth.  Proc Natl Acad Sci USA. 2001;  98 9306-9311
• 26 Lin C R, Yang L C, Lee T H, Lee C T, Huang H T, Sun W Z, Cheng J T. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats.  Gene Ther. 2002;  9 1247-1253
• 27 Losordo D W, Vale P R, Hendel R C, Milliken C E, Fortuin F D, Cummings N, Schatz R A, Asahara T, Isner J M, Kuntz R E. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia.  Circul. 2002;  105 2012-2018
• 28 Matsakas A, Diel P. The growth factor myostatin, a key regulator in skeletal muscle growth and homeostasis.  Int J Sports Med. 2005;  26 83-89
• 29 Nemunaitis J, Swisher S G, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence D D, Kemp B L, Fossella F, Glisson B S, Hong W K, Khuri F R, Kurie J M, Lee J J, Lee J S, Nguyen D M, Nesbitt J C, Perez-Soler R, Pisters K M, Putnam J B, Richli W R, Shin D M, Walsh G L, Merritt J, Roth J. Adenovirus-mediated p 53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.  J Clin Oncol. 2000;  18 609-622
• 30 Pound R. Sport where talent and genetic manipulations collide. Keynote address WADA health medical and research committee. Montreal; WADA 2002
• 31 Rajagopalan S, Mohler III E R, Lederman R J, Mendelsohn F O, Saucedo J F, Goldman C K, Blebea J, Macko J, Kessler P D, Rasmussen H S, Annex B H. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.  Circul. 2003;  108 1933-1938
• 32 Rankinen T, Perusse L, Rauramaa R, Rivera M A, Wolfarth B, Bouchard C. The human gene map for performance and health-related fitness phenotypes: the 2003 update.  Med Sci Sports Exerc. 2004;  36 1451-1469
• 33 Raper S E, Chirmule N, Lee F S, Wivel N A, Bagg A, Gao G P, Wilson J M, Batshaw M L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.  Mol Genet Metab. 2003;  80 148-158
• 34 Schuelke M, Wagner K R, Stolz L E, Hubner C, Riebel T, Komen W, Braun T, Tobin J F, Lee S J. Myostatin mutation associated with gross muscle hypertrophy in a child.  N Engl J Med. 2004;  350 2682-2688
• 35 Smith O. Nota bene: biomedicine. Pain-killer genes.  Sci. 1999;  284 1634
• 36 Tenenbaum L, Lehtonen E, Monahan P E. Evaluation of risks related to the use of adeno-associated virus-based vectors.  Curr Gene Ther. 2003;  3 545-565
• 37 Tio R A, Wijpkema J S, Tan E S, Asselbergs F W, Hospers G A, Jessurun G A, Zijlstra F. Functional characteristics of coronary vasomotor function following intramyocardial gene therapy with naked DNA encoding for vascular endothelial growth factor 165.  Endothelium. 2005;  12 103-106
• 38 Vitravene Study Group . A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS.  Am J Ophthalmol. 2002;  133 467-474
• 39 WADA .The world anti-doping code. The 2006 prohibited list. International standard. Keynote address WADA health medical and research committee. 1-1-2005. Montreal; WADA 2005
• 40 Wu W, Tang X, Hu W, Lotan R, Hong W K, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry.  Clin Exp Metastasis. 2002;  19 319-326
• 41 Ye X, Rivera V M, Zoltick P, Cerasoli Jr F, Schnell M A, Gao G, Hughes J V, Gilman M, Wilson J M. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer.  Sci. 1999;  283 88-91
• 42 Zhou S, Murphy J E, Escobedo J A, Dwarki V J. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates.  Gene Ther. 1998;  5 665-670